You are here: Home: Audio Program Guide: CCU 3 | 2006 Audio
 
  Go to interview with Edward Chu, MD
Go to interview with Robert A Wolff, MD
Go to interview with Howard A Burris III, MD
  To listen to individual tracks, click the on the headphone.
To download tracks, right-click on the one you wish to download.
Edward Chu, MD
Professor of Medicine and Pharmacology
Chief, Section of Medical Oncology
Deputy Director of Clinical Research
Yale Cancer Center
Yale School of Medicine
New Haven, Connecticut
  
  Click here to download the entire interview  
Track 1 Introduction
Track 2 Selection of adjuvant chemotherapy for colorectal cancer
Track 3 Use of capecitabine in the adjuvant and metastatic settings
Track 4 Dose and schedule of capecitabine
Track 5 Clinical use of capecitabine in the adjuvant setting
Track 6 Management of oxaliplatin-associated neurotoxicity
Track 7 Similarities and differences between panitumumab and cetuximab
Track 8 Potential advantages of adjuvant CAPOX compared to FOLFOX
Track 9 Staging and treatment of patients with rectal cancer
Track 10 Selection of chemotherapy to combine with radiation therapy in the treatment of rectal cancer
Track 11 Clinical algorithm for first-line therapy in patients without prior systemic therapy
Track 12 Clinical implications of TREE-1 and TREE-2 trial results
Track 13 Continuation of bevacizumab after disease progression
Track 14 Therapeutic approach to patients with isolated hepatic metastasis
Track 15 Future directions in the development of biologic agents in colorectal cancer
     
Robert A Wolff, MD
Associate Professor of Medicine
Deputy Chairman for Clinical Affairs
Department of Gastrointestinal Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas
  
  Click here to download the entire interview  
Track 1 Introduction
Track 2 Developing long-term strategies for the surgical and systemic treatment of metastatic disease
Track 3 Management of patients with synchronous primary and metastatic disease
Track 4 Impact of age on management of synchronous primary and metastatic disease
Track 5 Time course for surgery after preoperative bevacizumab
Track 6 Hepatic resection, ablation or the combination for hepatic metastases
Track 7 Applying oncologic “judgment” to management of hepatic metastases
Track 8 Clinical use of hepatic arterial infusion
Track 9 Necessity of developing criteria and standards for hepatic resection
Track 10 CAPOX versus FOLFOX in the adjuvant and metastatic settings
Track 11 Comparability of capecitabine and continuous infusion 5-FU in chemoradiation regimens for rectal cancer
Track 12 Convenience of neoadjuvant capecitabine versus infusional 5-FU for rectal cancer
Track 13 Role of downstaging clinical Stage III disease in selection of adjuvant chemotherapy
Track 14 Clinical trial of preoperative capecitabine/bevacizumab with radiation therapy in rectal cancer
Track 15 Potential mechanisms of action of bevacizumab
Track 16 Incorporation of oxaliplatin into neoadjuvant chemoradiation therapy for rectal cancer
Track 17 CONFIRM-1: FOLFOX with or without vatalanib as first-line therapy
Track 18 Effects of bevacizumab and chemotherapeutic agents on the liver
     
Howard A Burris III, MD
Director of Drug Development
Sarah Cannon Research Institute
Nashville, Tennessee
  
  Click here to download the entire interview  
Track 1 Introduction
Track 2 X-ACT adjuvant trial evaluating capecitabine versus the Mayo Clinic regimen
Track 3 European and United States dosing of capecitabine
Track 4 X-ACT trial: Efficacy and side-effect data
Track 5 Management of capecitabine-associated side effects
Track 6 Clinical use of adjuvant capecitabine monotherapy for colon cancer
Track 7 Patient perspectives on the value of benefits from adjuvant therapy
Track 8 Substitution of capecitabine for infusional 5-FU
Track 9 Impact of alternate schedules of capecitabine on tolerability
Track 10 Incorporating biologic agents into adjuvant clinical trials
Track 11 Clinical benefit of adding bevacizumab to chemotherapy for metastatic disease
Track 12 Continuation of bevacizumab after disease progression
Track 13 Use of aggressive surveillance for earlier detection of potentially curable disease
Track 14 Role of monoclonal antibodies targeting the EGFR in colorectal cancer
Track 15 Efficacy and tolerability of panitumumab monotherapy
Track 16 Difficulties in evaluating newly emerging agents in colorectal cancer
Track 17 Identification of predictors of response in colorectal cancer
Track 18 Need for predictive assays in colorectal cancer
Track 19 Development of oral tyrosine kinase inhibitors in breast and colon cancer